Squarepoint’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.89M | Buy |
+9,582
| New | +$1.85M | ﹤0.01% | 2224 |
|
|
2025
Q4 | – | Sell |
-90,237
| Closed | -$15.8M | – | 4260 |
|
|
2025
Q3 | $13.8M | Sell |
90,237
-42,847
| -32% | -$6.48M | 0.01% | 924 |
|
|
2025
Q2 | $18.6M | Buy |
133,084
+90,482
| +212% | +$12.7M | 0.02% | 798 |
|
|
2025
Q1 | $6.26M | Buy |
42,602
+34,611
| +433% | +$5.01M | 0.01% | 1293 |
|
|
2024
Q4 | $1.05M | Sell |
7,991
-63,026
| -89% | -$8.82M | ﹤0.01% | 3026 |
|
|
2024
Q3 | $11.1M | Buy |
71,017
+59,833
| +535% | +$9.66M | 0.02% | 911 |
|
|
2024
Q2 | $1.74M | Buy |
11,184
+9,684
| +646% | +$1.46M | ﹤0.01% | 2150 |
|
|
2024
Q1 | $203K | Sell |
1,500
-255,909
| -99% | -$33.9M | ﹤0.01% | 3610 |
|
|
2023
Q4 | $34.7M | Buy |
257,409
+201,171
| +358% | +$26.2M | 0.07% | 329 |
|
|
2023
Q3 | $7.62M | Sell |
56,238
-7,513
| -12% | -$1.03M | 0.02% | 927 |
|
|
2023
Q2 | $9.13M | Buy |
63,751
+32,694
| +105% | +$4.81M | 0.03% | 728 |
|
|
2023
Q1 | $4.31M | Sell |
31,057
-21,909
| -41% | -$2.95M | 0.02% | 961 |
|
|
2022
Q4 | $7.18M | Buy |
52,966
+819
| +2% | +$103K | 0.03% | 662 |
|
|
2022
Q3 | $5.72M | Buy |
52,147
+33,767
| +184% | +$4.28M | 0.03% | 679 |
|
|
2022
Q2 | $2.43M | Buy |
+18,380
| New | +$2.41M | 0.01% | 1066 |
|
|
2022
Q1 | – | Sell |
-18,121
| Closed | -$2.11M | – | 2816 |
|
|
2021
Q4 | $2.11M | Buy |
18,121
+10,041
| +124% | +$1.18M | 0.01% | 1224 |
|
|
2021
Q3 | $971K | Buy |
+8,080
| New | +$941K | ﹤0.01% | 1580 |
|
|
2021
Q2 | – | Sell |
-52,894
| Closed | -$5.26M | – | 3217 |
|
|
2021
Q1 | $5.26M | Buy |
52,894
+25,360
| +92% | +$2.55M | 0.03% | 607 |
|
|
2020
Q4 | $2.75M | Buy |
27,534
+9,468
| +52% | +$1M | 0.02% | 770 |
|
|
2020
Q3 | $1.98M | Sell |
18,066
-32,353
| -64% | -$3.6M | 0.03% | 652 |
|
|
2020
Q2 | $5.33M | Buy |
+50,419
| New | +$5.21M | 0.09% | 324 |
|
|
2020
Q1 | – | Sell |
-98,747
| Closed | -$9.85M | – | 1861 |
|
|
2019
Q4 | $9.85M | Buy |
98,747
+23,604
| +31% | +$2.22M | 0.06% | 307 |
|
|
2019
Q3 | $6.7M | Buy |
75,143
+24,578
| +49% | +$2.13M | 0.06% | 390 |
|
|
2019
Q2 | $4.17M | Buy |
+50,565
| New | +$3.96M | 0.04% | 495 |
|
|
2019
Q1 | – | Sell |
-5,777
| Closed | -$439K | – | 2137 |
|
|
2018
Q4 | $439K | Buy |
+5,777
| New | +$451K | 0.01% | 1322 |
|
|
2017
Q4 | – | Sell |
-15,602
| Closed | -$1.06M | – | 2076 |
|
|
2017
Q3 | $1.06M | Buy |
+15,602
| New | +$986K | 0.02% | 705 |
|
|
2017
Q1 | – | Sell |
-4,692
| Closed | -$256K | – | 1524 |
|
|
2016
Q4 | $256K | Buy |
+4,692
| New | +$266K | 0.01% | 1253 |
|
Other funds holding AZN
IA
VCM
VAM
Squarepoint's AZN Position: Q1 2026 in Review
Squarepoint opened a new position in AstraZeneca (AZN) in Q1 2026: 9,582 shares worth $1.89M. The stake represents ﹤0.01% of the portfolio and ranks #2224 among its holdings. This is a return to the name: Squarepoint previously reported a position in AZN as recently as Q3 2025.
Squarepoint first reported a position in AZN in Q4 2016 and has held it in 27 quarters since. The position peaked at $34.7M in Q4 2023. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Squarepoint held 9,582 shares of AstraZeneca worth $1.89M as of Q1 2026.
- AstraZeneca was a new Squarepoint position in Q1 2026.
- AstraZeneca made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2224 holding.
- Squarepoint first reported a position in AstraZeneca in Q4 2016 and has held it in 27 quarters since.
- Squarepoint's AstraZeneca position peaked at $34.7M in Q4 2023.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.